Cell Therapy in CV Disease: Future Directions. 2 Anversa P, Nadal-Ginard B et al. Nature. 2002;415:240-3. Cardiac renewal: Is the goal in sight? “Remaining.

Slides:

Advertisements

Similar presentations

Jay H. Traverse, MD Principal Investigator, TIME Study Minneapolis Heart Institute at Abbott Northwestern Hospital University of Minnesota Medical School.

Advertisements

Advances and Emerging Therapy for Lung Cancer

Kai Pinkernell, MD 4 th Int. Symp. Stem Cell Therapy & CV Biology Madrid, Spain 26 th of April 2007 Adipose Derived Stem Cell Therapy in Cardiovascular.

Treatment-Resistant Hypertension: Magnitude of the Problem Power Over Pressure

Department of Cardiovascular Medicine John Radcliffe Hospital, Oxford

4th International Symposium on Stem Cell Therapy Madrid, April 26-27, 2007 Stem Cell Thertapy for STEMI. Is is Time for a Large Scale Clinical Trial ?

prognosis of patients with Acute Myocardial Infarction remains dismal.

Jay H. Traverse, MD Principal Investigator, TIME Study Minneapolis Heart Institute at Abbott Northwestern Hospital University of Minnesota Medical School.

Therapeutic Peptides for Cardiovascular Disease and Cancer Cam Patterson, MD, MBA, FACC, FAHA Ernest and Hazel Craige Distinguished Professor of Cardiovascular.

Faeze. Introduction  Stem cell therapy is certainly a promising area for research. These have the ability to give rise to many specialize cells in on.

Cardiovascular Disease: Predicting Risk and Monitoring Outcomes Monica R. Shah, MD, FACC NHLBI AIDS Coordinator Conference on Retroviruses and Opportunistic.

Stem Cell Therapy Briana Lolo. Statistics Coronary heart disease is the most common type of heart disease, killing more than 385,000 people annually.

INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center

Stem Cell Implants to Repair Damaged Hearts Rationale Two clinical trials – Cardiac-derived stem cells Cedars Sinai Medical Center, Dr. Eduardo Marban.

Stem cells and gene therapy to repair the damaged heart: will it work and is it right? John Martin Professor of Cardiovascular Medicine University College.

Stem cell therapy in cardiac practice

(Title of Presentation) (Subtitle of Presentation) August 8, 2007 Hematologic Cancers Partners Meeting Centers for Disease Control and Prevention May 16,

1 FDA Regulation of Cell Therapy Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies Fourth Annual Translational Stem.

Stem cell therapy: what a cardiologist needs to know Robert Roberts MD Chief of Cardiology Baylor College of Medicine Houston, Texas Piero Anversa MD Director,

Jay H. Traverse, MD Principal Investigator, TIME Study Minneapolis Heart Institute at Abbott Northwestern Hospital University of Minnesota Medical School.

Emerson C Perin, MD, PhD Principal Investigator Texas Heart Institute, St. Luke’s Episcopal Hospital Cardiovascular Cell Therapy Research Network Effect.

Ongoing Trials in Managing Myocardial Ischemia. MERLIN-TIMI 36: Study design IV/oral ranolazinePlacebo Patients with non-ST elevation ACS treated with.

Advances in Stem Cell Therapy Karim Nayernia Professor of Human Genetics & Stem Cell Biology.

Stem Cell Therapy & CV Innovations Madrid, April , 2009 Next Steps in Heart Replacement My Clinical View William Wijns Cardiovascular.

False Positive ST Elevation in Patients Undergoing Direct Percutaneous Coronary Intervention David M. Larson MD, Katie M. Menssen, BS,, Scott W Sharkey.

New Organizational Models for Optimal Cell Processing and Application Robert D. Simari Chair, Cardiovascular Research Professor of Medicine Madrid 2009.

Jasna Marinović, M.D., Ph.D. Associate Professor Department of Physiology.

Enrollment and Monitoring Procedures for NCI Supported Clinical Trials Barry Anderson, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute.

Jay H Traverse, MD Principal Investigator, LateTIME Study Minneapolis Heart Institute at Abbott Northwestern Hospital University of Minnesota Medical School.

Late Open Artery Hypothesis Jason S. Finkelstein, M.D. Tulane University Medical Center 2/24/03.

Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.

CR-1 Candesartan in HF Benefit/Risk James B. Young, MD Cleveland Clinic Foundation.

Regeneration and stem cells Definition 1) Self-renewing capability  Clonal expansion 2) Differentiation into various types of cells, multipotent = self.

Why Treat Patent Forman Ovale Clifford J Kavinsky, MD, PHD Professor of Medicine and pediatrics Associate Director, Center for Congenital and Structural.

Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.

I farmaci innovativi in una prospettiva europea Giuseppe M.C. Rosano, MD, PhD Cardiovascular and Cell Sciences Research Institute, St George's University.

No conflicts of interest or financial ties to disclose.

KOA Conference Eldoret 2016 Mutiso VM, Anzala O, Khainga SO, Otieno C, Ogalo JP, Bundi BN.

IN THE NAME OF GOD. What are Stem Cells? Stem cells are a class of undifferentiated cells that are able to differentiate into specialized cell types.

Pax 7 is Necessary For the Myogenic Specification of CD45+ Stem Cells Reviewed by Heather Hall Research by Patrick Seale, Jeff Ishibashi, Anthony Scime,

Skeletal Myoblast Cells. 2 Skeletal myoblasts Derived from satellite cells in skeletal muscle With appropriate stimulus, satellite cells differentiate.

Clinical Outcomes with Newer Antihyperglycemic Agents

12/4/2017 3:49 AM PACE PACE Patients with Intermittent Claudication Injected with ALDH Bright Cells AHA 2016 November 14, 2016 Emerson C Perin, MD, PhD.

The TIME Randomized Trial:

Cell Repair Therapy – Phase 1 Lessons Learned – Clinical Studies

The NHLBI TIME Trial: Role of Microvascular Obstruction in 2-Year Clinical and MRI Follow-up Jay H. Traverse, MD Principal Investigator, TIME Study Minneapolis.

Clinical Outcomes with Newer Antihyperglycemic Agents

The role of unknown risk factors in coronary heart disease

Maury S et al. Proc ASH 2015;Abstract 1.

Revascularization in Patients With Left Ventricular Dysfunction:

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

On-Site Surgical Back-up is ‘Critically’ Important for PCI!

United States Preventive Services Task Force: Recommendations for ABPM

Valsartan in Acute Myocardial Infarction Trial Investigators

Acute Heart Failure.

EULAR Lupus Nephritis Trials Network Study Group 2017

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

Cardiac Cell Repair Therapy: A Clinical Perspective

Cardiac stem cell therapy: Checkered past, promising future?

Expert Insights on Complex Clinical Cases of Edema

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

EMERGING ROLE OF STEM CELLS In CARDIOVASCULAR THERAPY

G. Michael Felker et al. JCHF 2014;2:

Zhi Cui, MSc, Ren-Ke Li, MD, PhD

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

EULAR Lupus Nephritis Trials Network Study Group

Stem Cell Research.

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Presentation transcript:

Cell Therapy in CV Disease: Future Directions

2 Anversa P, Nadal-Ginard B et al. Nature. 2002;415: Cardiac renewal: Is the goal in sight? “Remaining young at heart is a desirable but elusive goal. Myocyte regeneration may accomplish just that. Continuous cell renewal in adult myocardium was thought to be impossible; multipotent stem cells may be able to renew myocardium and, under certain circumstances, can be coaxed to repair the broken heart after infarction.”

3 Stem cell therapy: More questions than answers? Routes of delivery Surgical vs percutaneous Cell type and marker Myoblast vs BM CD 34/ AC133/ SP Timing of delivery Acute vs chronic Target patient population Best criteria Cell origin Embryonic vs adult BM vs peripheral Culture expanded vs fresh Courtesy of Timothy Henry, MD. ? Dose Dose response

4 CCTRN: Addressing gaps in the knowledge base NHLBI Cardiovascular Cell Therapy Research Network, established January 2007 Nat Clin Pract Cardiovasc Med. 2007;4:403. DCC = Data Coordinating Center MHI = Minneapolis Heart Institute Network DCC University of Texas Network DCC University of Texas Universit y of Florida Vanderbil t Universit y Cleveland Clinic MHI U of Minn Texas Heart Institute

5 CCTRN: Goal and initial phase I/II clinical trials Nat Clin Pract Cardiovasc Med. 2007;4:403. Goal: Accelerate research into use of cell-based therapies in management of CV diseases TIME Effect of timing of post-MI BMC administration on measures of LV function Late TIME Effect of late (2-3 weeks) post-MI BMC administration on measures of LV function FOCUS Effect of transmyocardial BMC administration on measures of LV function in patients with chronic IHD

6 Year 02Year 01Year 03Year 05 PRC DSMB Review Protocol 1 Development Protocol 1 Protocol 2 Development PRC DSMB Review Protocol 2 Protocol 3 Development Protocol 3 PRC DSMB Review Courtesy Timothy Henry, MD. CCTRN: Timeline of trials Year 04

7 Summary Current clinical efforts have focused in three overlapping areas: –Repair of myocardium after MI –Reconstitution of myocardium in setting of chronic HF –Therapeutic angiogenesis Promising early clinical experience with BMC, endothelial cells, and skeletal myoblasts Numerous questions regarding techniques and mechanism of benefit remain –Ongoing trials by the NHLBI CCTRN and other research groups should provide insight